What is Novocure?
Novocure is a global oncology enterprise dedicated to extending survival rates for patients diagnosed with some of the most aggressive forms of cancer. The company's core innovation, Tumor Treating Fields, utilizes electric fields to disrupt cancer cell division, offering a non-invasive alternative or adjunct to traditional chemotherapy and radiation. With commercial approvals for glioblastoma and malignant pleural mesothelioma, Novocure maintains a robust pipeline of clinical trials targeting brain metastases, gastric cancer, and non-small cell lung cancer. Headquartered in Jersey with a sprawling international presence, the company integrates advanced engineering with clinical rigor to redefine standard-of-care protocols.
How much funding has Novocure raised?
Novocure has raised a total of $708M across 3 funding rounds:
Stock Offering
$158M
Debt
$150M
Debt
$400M
Stock Issuance/Offering (2015): $158M with participation from Undisclosed
Debt (2018): $150M led by BioPharma Credit PLC
Debt (2024): $400M supported by Pharmakon Software
Key Investors in Novocure
Pharmakon Software
Pharmakon Software GmbH specializes in omnichannel CRM and digital sales solutions tailored for the pharmaceutical and life sciences sectors, focusing on compliance and operational efficiency.
BioPharma Credit PLC
A specialized investment firm providing debt financing solutions to the life sciences industry, focusing on companies with late-stage clinical assets.
Undisclosed Investors
What's next for Novocure?
With the recent capital infusion, Novocure is expected to prioritize the expansion of its clinical trial infrastructure and the commercial rollout of its TTFields therapy in key international markets. The strategic focus will likely shift toward data-driven market penetration and the optimization of its supply chain to support broader patient access. As the company moves deeper into its enterprise-level growth phase, the integration of advanced digital sales and CRM solutions—supported by strategic partners—will be instrumental in maintaining its competitive edge. Investors will be closely monitoring the readout of ongoing trials, as positive results could significantly broaden the addressable patient population and drive long-term shareholder value.
See full Novocure company page
